Skip to main content
. 2025 Nov 17;19:2037. doi: 10.3332/ecancer.2025.2037

Table 2. Adverse effects across trials [12, 23].

Trial name Grade ≥3 AEs (%) Notable specific AEs
CHRYSALIS (NCT02609776) 35% (Amivantamab monotherapy) Rash (86% all-grade, 3% grade ≥3), IRRs (66%, mostly grade 1–2), paronychia (45%)
PAPILLON (NCT04538664) Ami + Chemo: 75% versus Chemo: 54% Neutropenia (59% all grade, 33% grade ≥3), rash (54% all-grade, 11 grade ≥3), paronychia (56%)

AEs = adverse effects; Ami = amivantamab; Chemo = chemotherapy. Original table